MARKET

SABS

SABS

SAB BIOTHERAPEUTICS INC
NASDAQ
1.880
-0.100
-5.05%
Opening 13:41 05/13 EDT
OPEN
2.010
PREV CLOSE
1.980
HIGH
2.010
LOW
1.862
VOLUME
22.48K
TURNOVER
0
52 WEEK HIGH
5.01
52 WEEK LOW
1.000
MARKET CAP
17.47M
P/E (TTM)
-0.5106
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SABS last week (0505-0509)?
Weekly Report · 1d ago
SAB Biotherapeutics, Inc. Reports Financial Results for the Quarter Ended March 31, 2025
Press release · 4d ago
SAB Biotherapeutics reports Q1 results
Seeking Alpha · 4d ago
*SAB Biotherapeutics 1Q Research and Development Expenses $7.7M >SABS
Dow Jones · 4d ago
Press Release: SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
Dow Jones · 4d ago
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
Barchart · 4d ago
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 6d ago
Weekly Report: what happened at SABS last week (0428-0502)?
Weekly Report · 05/05 11:12
More
About SABS
More
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
Recently
Symbol
Price
%Change

Webull offers SAB Biotherapeutics Inc stock information, including NASDAQ: SABS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SABS stock methods without spending real money on the virtual paper trading platform.